Zoetis Inc. Federal State And Local Income Tax Expense Benefit Continuing Operations
Zoetis Inc. (ZTS) reported Federal State And Local Income Tax Expense Benefit Continuing Operations of $409.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-12
- Zoetis Inc. federal state and local income tax expense benefit continuing operations for fiscal 2025 was $409.00M, a 10.24% increase from fiscal 2024.
- Zoetis Inc. federal state and local income tax expense benefit continuing operations for fiscal 2024 was $371.00M, a 2.77% increase from fiscal 2023.
- Zoetis Inc. federal state and local income tax expense benefit continuing operations for fiscal 2023 was $361.00M.
| Period end | Federal State And Local Income Tax Expense Benefit Continuing Operations 12 month |
|---|---|
| 2025-12-31 | $409.00M 10-K · filed 2026-02-12 |
| 2024-12-31 | $371.00M 10-K · filed 2026-02-12 |
| 2023-12-31 | $361.00M 10-K · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |